ALLO
Allogene Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.19
+6.25%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.16
From 52W high−61.11%
Volume16.52M
Market cap$411.13M
P/E (TTM)—
P/S (TTM)88.6x
Div yield—
Key dataNov 4, 2026
Open
$1.16
From 52W high
−61.11%
Volume
16.52M
Market cap
$411.13M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
P/E (TTM)
—
RSI (14)
28.7
MomentumView details →
1D Return
+6.25%
YTD Return
−18.25%
SummaryUpdated Jun 1, 2026
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage immuno-oncology biotechnology company founded in 2017 and headquartered in South San Francisco, California. The company went public in October 2018 and has positioned itself as a pioneer in developing "off-the-shelf" allogeneic CAR T cell therapies for cancer treatment and autoimmune diseases. Unlike traditional CAR T therapies that require extracting and modifying a patient's own immune cells, Allogene's approach uses genetically engineered T cells from healthy donors that can be manufactured in advance and stored for immediate use when needed.
Similar companies
Latest newsMore news →
Allogene Therapeutics, Inc. announced two investor events in November 2026 to present its third-quarter results and initial clinical data from the ALLO-329 autoimmune disease program.7d agoAllogene Therapeutics announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, 2026.64d ago